New Drug Combination Targets Genetic Weakness in Pancreatic Cancer
Researches have presented a new treatment strategy for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with a survival rate of about 13%. While most PDAC cases have KRAS mutations, around 22% also lose the MTAP gene. This MTAP deletion causes a buildup of a molecule called MTA, creating a unique weakness in cancer cells. Researchers developed a […]
New Drug Combination Targets Genetic Weakness in Pancreatic Cancer Read More »